Human challenge trials in vaccine development.

Amrita Sekhar, Gagandeep Kang
Author Information
  1. Amrita Sekhar: Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.
  2. Gagandeep Kang: Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India. Electronic address: gkang@cmcvellore.ac.in.

Abstract

The increasing recent interest in human challenge studies or controlled human infection model studies for accelerating vaccine development has been driven by the recognition of the unique ability of these studies to contribute to the understanding of response to infection and the performance of vaccines. With streamlining of ethical processes, conduct and supervision and the availability of new investigative tools from immunophenotyping to glycobiology, the potential to derive valuable data to inform vaccine testing and development has never been greater. However, issues of availability and standardization of challenge strains, conduct of studies in disease endemic locations and the iteration between clinical and laboratory studies still need to be addressed to gain maximal value for vaccine development.

Keywords

References

  1. Lancet. 2017 Dec 2;390(10111):2472-2480 [PMID: 28965718]
  2. Trials. 2019 Dec 19;20(Suppl 2):702 [PMID: 31852506]
  3. P T. 2017 Oct;42(10):638-640 [PMID: 29018300]
  4. Trends Parasitol. 2017 Feb;33(2):141-150 [PMID: 27956060]
  5. Rev Infect Dis. 1989 May-Jun;11 Suppl 3:S552-67 [PMID: 2669099]
  6. Wellcome Open Res. 2018 Dec 6;3:155 [PMID: 31803847]
  7. Infect Immun. 2017 Dec 19;86(1): [PMID: 28923897]
  8. mSphere. 2019 Feb 13;4(1): [PMID: 30760615]
  9. Nat Rev Immunol. 2011 Jan;11(1):57-64 [PMID: 21179119]
  10. Am J Trop Med Hyg. 2013 Jan;88(1):5-13 [PMID: 23149582]
  11. Biologicals. 2016 Jan;44(1):37-50 [PMID: 26611523]
  12. J Infect Dis. 2012 Aug 1;206(3):319-23 [PMID: 22615322]
  13. Future Microbiol. 2012 Apr;7(4):481-95 [PMID: 22439725]
  14. J Med Ethics. 2004 Feb;30(1):110-6 [PMID: 14872087]
  15. Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2711-2716 [PMID: 28223498]
  16. Clin Infect Dis. 2019 Aug 16;69(5):877-883 [PMID: 30624673]
  17. Biologicals. 2019 Sep;61:85-94 [PMID: 29573967]
  18. J Infect Dis. 2020 May 11;221(11):1752-1756 [PMID: 32232474]
  19. Vaccine. 2019 Jul 18;37(31):4256-4261 [PMID: 31235375]
  20. Vaccine. 2019 Jun 6;37(26):3485-3494 [PMID: 31101422]
  21. Clin Infect Dis. 2020 Jul 11;71(2):403-411 [PMID: 31562530]
  22. Biologicals. 2020 Jul;66:41-52 [PMID: 32505512]
  23. PLoS Negl Trop Dis. 2016 Oct 19;10(10):e0005070 [PMID: 27760143]
  24. J Infect Dis. 2009 Aug 1;200(3):337-46 [PMID: 19569965]
  25. JAMA. 1969 Feb 10;207(6):1115-9 [PMID: 5818242]
  26. Infect Immun. 1998 May;66(5):1968-72 [PMID: 9573077]
  27. AAS Open Res. 2019 Aug 13;2:17 [PMID: 31819922]
  28. Clin Infect Dis. 2016 Jun 1;62(11):1329-1335 [PMID: 27001804]
  29. J Infect Dis. 1974 Apr;129(4):385-90 [PMID: 4593870]
  30. Clin Infect Dis. 2014 May;58(9):1230-40 [PMID: 24519873]
  31. Vaccine. 2017 Jul 24;35(33):4064-4071 [PMID: 28647170]
  32. Vaccine. 2012 Aug 3;30(36):5302-4 [PMID: 22659449]
  33. Lancet Infect Dis. 2020 Aug;20(8):e198-e203 [PMID: 32479747]
  34. Indian J Med Ethics. 2018 Oct-Dec;3(4):263-266 [PMID: 30473497]
  35. PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423 [PMID: 26919472]
  36. Am J Respir Crit Care Med. 2021 Mar 1;203(5):604-613 [PMID: 32941735]
  37. Lancet Infect Dis. 2018 Oct;18(10):e312-e322 [PMID: 29891332]
  38. J Infect Dis. 2020 Jul 6;222(3):514-516 [PMID: 32496536]
  39. Hastings Cent Rep. 1982 Apr;12(2):5-7 [PMID: 7096065]
  40. Proc (Bayl Univ Med Cent). 2005 Jan;18(1):21-5 [PMID: 16200144]
  41. AAS Open Res. 2018 Apr 18;1:2 [PMID: 30714021]
  42. J Infect Dis. 2017 Dec 16;216(suppl_10):S971-S975 [PMID: 29267920]
  43. J Infect Dis. 2018 Aug 24;218(7):1142-1146 [PMID: 29905805]
  44. Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S22-S26 [PMID: 30767002]
  45. Wellcome Open Res. 2017 Aug 24;2:70 [PMID: 29018841]
  46. Public Health Ethics. 2016 Apr;9(1):92-103 [PMID: 29731811]
  47. Nat Med. 2020 Mar;26(3):326-332 [PMID: 32066978]
  48. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11 [PMID: 21292872]
  49. Lancet. 2015 Jul 4;386(9988):31-45 [PMID: 25913272]
  50. Front Microbiol. 2014 Dec 12;5:686 [PMID: 25566206]
  51. Clin Infect Dis. 2015 Aug 1;61(3):393-402 [PMID: 25870324]
  52. Nature. 2019 Apr 16;: [PMID: 32291409]
  53. Lancet Infect Dis. 2015 Jul;15(7):840-51 [PMID: 26026195]
  54. Lancet Infect Dis. 2005 Nov;5(11):685-94 [PMID: 16253886]
  55. N Engl J Med. 2019 Dec 5;381(23):2209-2218 [PMID: 31800986]

Grants

  1. MR/R005982/1/Medical Research Council

MeSH Term

Clinical Trials as Topic
Humans
Infections
Research
Vaccination
Vaccines

Chemicals

Vaccines

Word Cloud

Created with Highcharts 10.0.0studieschallengeinfectionvaccinedevelopmenthumanHumanconductavailabilityincreasingrecentinterestcontrolledmodelacceleratingdrivenrecognitionuniqueabilitycontributeunderstandingresponseperformancevaccinesstreamliningethicalprocessessupervisionnewinvestigativetoolsimmunophenotypingglycobiologypotentialderivevaluabledatainformtestingnevergreaterHoweverissuesstandardizationstrainsdiseaseendemiclocationsiterationclinicallaboratorystillneedaddressedgainmaximalvaluetrialsControlledmodelsVaccines

Similar Articles

Cited By